株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ループス腎炎(LN)- 市場洞察、疫学、市場予測 2028年

Lupus Nephritis (LN) - Market Insights, Epidemiology and Market Forecast-2028

発行 DelveInsight Business Research LLP 商品コード 534783
出版日 ページ情報 英文 162 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
ループス腎炎(LN)- 市場洞察、疫学、市場予測 2028年 Lupus Nephritis (LN) - Market Insights, Epidemiology and Market Forecast-2028
出版日: 2019年08月01日 ページ情報: 英文 162 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)のループス腎炎(LN)の2017年の有病者数は19万819人、市場規模は13億6,000万米ドルと推定されました。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)のループス腎炎(LN)市場を調査し、市場の概要、性別・クラス別の有病数の推移と予測、国別の詳細動向、治療薬の概要および市場規模、市場の成長要因および参入障壁などについてまとめています。

目次

第1章 重要洞察

第2章 ループス腎炎(LN):市場概要

  • 市場シェア・ループス腎炎(LN)の分布(実数値)
  • 市場シェア・ループス腎炎(LN)の分布(予測値)

第3章 ループス腎炎(LN):疾患背景と概要

  • イントロダクション
  • 原因
  • 危険因子
  • 症状
  • その他の臨床症状
  • 予後
  • 臨床症状
  • 病因
  • 分類
    • 世界保健機関による分類(1964年)
    • 世界保健機関による形態学的分類(1982年改定)
    • 国際腎臓学会(ISN)および腎病理学会(RPS)による分類(2003年)
  • 診断

第4章 疫学と患者人口

  • 主な調査結果

第5章 主要7カ国の総有病数

第6章 ループス腎炎(LN)の疫学:国別

  • 米国
    • 仮定と根拠
    • 総有病数
    • 総診断数
    • 有病数:性別
    • 有病数:クラス別
    • 臨床症状
  • 欧州5カ国
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • スペイン
  • 日本

第7章 治療

  • 治療目標
  • 治療薬
  • 一般的な治療
  • 治療ガイドライン
    • ループス腎炎(LN)のスクリーニング、治療、および管理に関する米国リウマチ学会ガイドライン
    • ループス腎炎(LN)の治療に関するEULARガイドライン
    • ループス腎炎(LN)の治療に関するKDIGOガイドライン

第8章 アンメットニーズ

第9章 上市済み治療薬

  • プログラフ:アステラス製薬
    • 医薬品概要
    • 規制のマイルストーン
    • その他の開発動向
    • 安全性と有効性
    • 製品プロファイル

第10章 主なクロスコンペティター

第11章 新薬

  • Obinutuzumab:Roche
    • 製品説明
    • その他の開発動向
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • Belimumab:GlaxoSmithKline
    • その他の開発活動
  • Voclosporin:Aurinia Pharmaceuticals
  • Anifrolumab:AstraZeneca
    • 製品の開発動向

第12章 その他の有望な候補薬

  • BI 655064:Boehringer Ingelheim
    • 製品説明
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • Iscalimab:Novartis
    • 製品の開発動向

第13章 主要7カ国のループス腎炎(LN)市場

  • 主な調査結果
  • ループス腎炎(LN)の総市場規模
  • ループス腎炎(LN)の市場規模:第一選択薬別
  • ループス腎炎(LN)の市場規模:第二選択薬別

第14章 米国市場の見通し

  • 米国の市場規模
    • ループス腎炎(LN)の総市場規模
    • ループス腎炎(LN)の市場規模:第一選択薬別
    • ループス腎炎(LN)の市場規模:第二選択薬別

第15章 欧州5カ国市場の見通し

  • ドイツの市場規模
    • ループス腎炎(LN)の総市場規模
    • ループス腎炎(LN)の市場規模:第一選択薬別
    • ループス腎炎(LN)の市場規模:第二選択薬別
  • フランス
  • イタリア
  • 英国
  • スペイン

第16章 日本市場の見通し

  • 日本の市場規模
    • ループス腎炎(LN)の総市場規模
    • ループス腎炎(LN)の市場規模:第一選択薬別
    • ループス腎炎(LN)の市場規模:第二選択薬別

第17章 市場成長要因

第18章 市場の障壁

第19章 付録

  • 報告方法

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Prevalent Population of LN in the 7MM (2017-2028)
  • Table 2: Total Prevalent Population of LN in the US (2017-2028)
  • Table 3: Diagnosed Cases of LN in the US (2017-2028)
  • Table 4: Gender Specific Prevalence of LN in the US (2017-2028)
  • Table 5: Class specific cases of LN in the US (2017-2028)
  • Table 6: Clinical Manifestations of LN in the US (2017-2028)
  • Table 7: Total Prevalent Population of LN in Germany (2017-2028)
  • Table 8: Diagnosed Cases of LN in Germany (2017-2028)
  • Table 9: Gender Specific Prevalence of LN in Germany (2017-2028)
  • Table 10: Class specific cases of LN in Germany (2017-2028)
  • Table 11: Clinical Manifestations of LN in Germany (2017-2028)
  • Table 12: Total Prevalent Population of LN in France (2017-2028)
  • Table 13: Diagnosed Cases of LN in France (2017-2028)
  • Table 14: Gender Specific Prevalence of LN in France (2017-2028)
  • Table 15: Class specific cases of LN in France (2017-2028)
  • Table 16: Clinical Manifestations of LN in France (2017-2028)
  • Table 17: Total Prevalent Population of LN in Italy (2017-2028)
  • Table 18: Diagnosed Cases of LN in Italy (2017-2028)
  • Table 19: Gender Specific Prevalence of LN in Italy (2017-2028)
  • Table 20: Class specific cases of LN in Italy (2017-2028)
  • Table 21: Clinical Manifestations of LN in Italy (2017-2028)
  • Table 22: Total Prevalent Population of LN in The United Kingdom (2017-2028)
  • Table 23: Diagnosed Cases of LN in The United Kingdom (2017-2028)
  • Table 24: Gender Specific Prevalence of LN in The United Kingdom (2017-2028)
  • Table 25: Class specific cases of LN in The United Kingdom (2017-2028)
  • Table 26: Clinical Manifestations of LN in The United Kingdom (2017-2028)
  • Table 27: Total Prevalent Population of LN in Spain (2017-2028)
  • Table 28: Diagnosed Cases of LN in Spain (2017-2028)
  • Table 29: Gender Specific Prevalence of LN in Spain (2017-2028)
  • Table 30: Class specific cases of LN in Spain (2017-2028)
  • Table 31: Clinical Manifestations of LN in Spain (2017-2028)
  • Table 32: Total Prevalent Population of LN in Japan (2017-2028)
  • Table 33: Diagnosed Cases of LN in Japan (2017-2028)
  • Table 34: Gender Specific Prevalence of LN in Japan (2017-2028)
  • Table 35: Class specific cases of LN in Japan (2017-2028)
  • Table 36: Clinical Manifestations of LN in Japan (2017-2028)
  • Table 37: Guidelines compared; common views and differences
  • Table 38:: Key Cross Emerging Therapies
  • Table 39:: Key Cross Emerging Therapies
  • Table 40: Obinutuzumab, Clinical Trial Description, 2019
  • Table 41: Belimumab, Clinical Trial Description, 2019
  • Table 42: Voclosporin, Clinical Trial Description, 2019
  • Table 43: Anifrolumab, Clinical Trial Description, 2019
  • Table 44: BI 655064, Clinical Trial Description, 2019
  • Table 45: Iscalimab, Clinical Trial Description, 2019
  • Table 46: 7 Major Market Size of LN in USD Million (2017-2028)
  • Table 47: 7 Major Market Size by Therapies for First Line Patients of LN in USD Million (2017-2028)
  • Table 48:7 Major Market Size by Therapies for Second Line Patients of LN in USD Million (2017-2028)
  • Table 49: Market Size of LN in the US, USD Million (2017-2028)
  • Table 50: USA Market Size by Therapies for First Line Patients of LN in USD Million (2017-2028)
  • Table 51: Market Size by Therapies for Second Line Patients of LN in The US, in USD Million (2017-2028)
  • Table 52: Market Size of LN in Germany, USD Million (2017-2028)
  • Table 53: Germany Market Size by Therapies for First Line Patients of LN in USD Million (2017-2028)
  • Table 54: Market Size by Therapies for Second Line Patients of LN in Germany, USD Million (2017-2028)
  • Table 55: Market Size of LN in France, USD Million (2017-2028)
  • Table 56: France Market Size by Therapies for First Line Patients of LN in USD Million (2017-2028)
  • Table 57: Market Size by Therapies for Second Line Patients of LN in France, USD Million (2017-2028)
  • Table 58: Market Size of LN in Italy, USD Million (2017-2028)
  • Table 59: Italy Market Size by Therapies for First Line Patients of LN in USD Million (2017-2028)
  • Table 60: Market Size by Therapies for Second Line Patients of LN in Italy, USD Million (2017-2028)
  • Table 61: Market Size of LN in The UK, USD Million (2017-2028)
  • Table 62: UK Market Size by Therapies for First Line Patients of LN in USD Million (2017-2028)
  • Table 63: Market Size by Therapies for Second Line Patients of LN in The UK, USD Million (2017-2028)
  • Table 64: Market Size of LN in Spain, USD Million (2017-2028)
  • Table 65: Spain Market Size by Therapies for First Line Patients of LN in USD Million (2017-2028)
  • Table 66: Market Size by Therapies for Second Line Patients of LN in Spain, USD Million (2017-2028)
  • Table 67: Market Size of LN in Japan, USD Million (2017-2028)
  • Table 68: Japan Market Size by Therapies for First Line Patients of LN in USD Million (2017-2028)
  • Table 69: Market Size by Therapies for Second Line Patients of LN in Japan, USD Million (2017-2028)

List of Figures

  • Figure 1: Clinical Manifestations of SLE and Lupus Nephritis
  • Figure 2: Risk Factors of Lupus Nephritis
  • Figure 3: Symptoms associated with Lupus Nephritis
  • Figure 4: Symptoms associated with Lupus Nephritis
  • Figure 5: Lupus Nephritis Pathogenesis
  • Figure 6: Therapeutic targets for LN
  • Figure 7: Pathomechanisms of LN outside the kidney
  • Figure 8: Therapeutic targets for LN
  • Figure 9: Total Prevalent Patient Population of LN in the 7MM (2017-2028)
  • Figure 10: Total Prevalent Population of LN in the US (2017-2028)
  • Figure 11: Diagnosed Cases of LN in the US (2017-2028)
  • Figure 12: Gender Specific Prevalence of LN in the US (2017-2028)
  • Figure 13: Class specific cases of LN in the US (2017-2028)
  • Figure 14: Clinical Manifestations of LN in the US (2017-2028)
  • Figure 15: Total Prevalent Population of LN in Germany (2017-2028)
  • Figure 16: Diagnosed Cases of LN in Germany (2017-2028)
  • Figure 17: Gender Specific Prevalence of LN in Germany (2017-2028)
  • Figure 18: Class specific cases of LN in Germany (2017-2028)
  • Figure 19: Clinical Manifestations of LN in Germany (2017-2028)
  • Figure 20: Total Prevalent Population of LN in France (2017-2028)
  • Figure 21: Diagnosed Cases of LN in France (2017-2028)
  • Figure 22: Gender Specific Prevalence of LN in France (2017-2028)
  • Figure 23: Class specific cases of LN in France (2017-2028)
  • Figure 24: Clinical Manifestations of LN in France (2017-2028)
  • Figure 25: Total Prevalent Population of LN in Italy (2017-2028)
  • Figure 26: Diagnosed Cases of LN in Italy (2017-2028)
  • Figure 27: Gender Specific Prevalence of LN in Italy (2017-2028)
  • Figure 28: Class specific cases of LN in Italy (2017-2028)
  • Figure 29: Clinical Manifestations of LN in Italy (2017-2028)
  • Figure 30: Total Prevalent Population of LN in The United Kingdom (2017-2028)
  • Figure 31: Diagnosed Cases of LN in The United Kingdom (2017-2028)
  • Figure 32: Gender Specific Prevalence of LN in The United Kingdom (2017-2028)
  • Figure 33: Class specific cases of LN in The United Kingdom (2017-2028)
  • Figure 34: Clinical Manifestations of LN in The United Kingdom (2017-2028)
  • Figure 35: Total Prevalent Population of LN in Spain (2017-2028)
  • Figure 36: Diagnosed Cases of LN in Spain (2017-2028)
  • Figure 37: Gender Specific Prevalence of LN in Spain (2017-2028)
  • Figure 38: Class specific cases of LN in Spain (2017-2028)
  • Figure 39: Clinical Manifestations of LN in Spain (2017-2028)
  • Figure 40: Total Prevalent Population of LN in Japan (2017-2028)
  • Figure 41: Diagnosed Cases of LN in Japan (2017-2028)
  • Figure 42: Gender Specific Prevalence of LN in Japan (2017-2028)
  • Figure 43: Class specific cases of LN in Japan (2017-2028)
  • Figure 44: Clinical Manifestations of LN in Japan (2017-2028)
  • Figure 45: Treatment approach for patients with lupus nephritis
  • Figure 46: Treatment approach for Refractory lupus nephritis
  • Figure 47: Therapeutic targets for LN
  • Figure 48: Therapeutic targets for LN
  • Figure 49: Unmet Needs of Lupus Nephritis
  • Figure 50: 7 Major Market Size of LN in USD Million (2017-2028)
  • Figure 51: 7 Major Market Size by Therapies for First Line Patients of LN in USD Million (2017-2028)
  • Figure 52: 7 Major Market Size by Therapies for Second Line Patients of LN in USD Million (2017-2028)
  • Figure 53: Mean adjusted total costs, total and by type of servcie
  • Figure 54: Average annual cost of illness per patient by condition
  • Figure 55: Market Size of LN in the US, USD Million (2017-2028)
  • Figure 56: Market Size of First Line Patients by Therapies for LN in the US, USD Million (2017-2028)
  • Figure 57: Market Size by Therapies for Second line Patients of LN in The US, USD Million (2017-2028)
  • Figure 58: Market Size of LN in Germany, USD Million (2017-2028)
  • Figure 59: Market Size of First Line Patients by Therapies for LN in Germany, USD Million (2017-2028)
  • Figure 60: Market Size by Therapies for Second line Patients of LN in Germany, USD Million (2017-2028)
  • Figure 61: Market Size of LN in France, USD Million (2017-2028)
  • Figure 62: Market Size of First Line Patients by Therapies for LN in France, USD Million (2017-2028)
  • Figure 63: Market Size by Therapies for Second line Patients of LN in France, USD Million (2017-2028)
  • Figure 64: Market Size of LN in Italy, USD Million (2017-2028)
  • Figure 65: Market Size of First Line Patients by Therapies for LN in Italy, USD Million (2017-2028)
  • Figure 66: Market Size by Therapies for Second line Patients of LN in Italy, USD Million (2017-2028)
  • Figure 67: Market Size of LN in The UK, USD Million (2017-2028)
  • Figure 68: Market Size of First Line Patients by Therapies for LN in The UK, USD Million (2017-2028)
  • Figure 69: Market Size by Therapies for Second line Patients of LN in The UK, USD Million (2017-2028)
  • Figure 70: Market Size of LN in Spain, USD Million (2017-2028)
  • Figure 71: Market Size of First Line Patients by Therapies for LN in Spain, USD Million (2017-2028)
  • Figure 72: Market Size by Therapies for Second line Patients of LN in Spain, USD Million (2017-2028)
  • Figure 73: Market Size of LN in Japan, USD Million (2017-2028)
  • Figure 74: Market Size of First Line Patients by Therapies for LN in Japan, USD Million (2017-2028)
  • Figure 75: Market Size by Therapies for Second line Patients of LN in Japan, USD Million (2017-2028)
  • Figure 76: Market Drivers
  • Figure 77: Market Barriers
目次
Product Code: DIMI0129

DelveInsight's 'Lupus Nephritis (LN) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of LN in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Lupus Nephritis (LN) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Lupus Nephritis (LN) - Disease Understanding and Treatment Algorithm

The DelveInsight Lupus Nephritis (LN) market report gives the thorough understanding of the Lupus Nephritis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Lupus Nephritis in the US, Europe, and Japan.

Lupus Nephritis Epidemiology

The Lupus Nephritis (LN) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, gender-specific prevalent cases, class-specific prevalent cases, clinical manifestations and diagnosed cases of LN) scenario of Lupus Nephritis (LN) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Lupus Nephritis (LN) in 7 MM was found to be 190,819, in the year 2017.

Lupus Nephritis Drug Chapters

This segment of the Lupus Nephritis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast solely focuses on the market revenue generated by the pharmacological treatment. The mainstays for addressing LN are mainly dominated with Glucocorticosteroids (Prednisone or methylprednisolone); Immunosuppressants (Cyclophosphamide, Azathioprine, Mycophenolate mofetil (MMF); Others (Monoclonal antibodies, such as Rituximab) and Adjunctive Therapies (such as Hydroxychloroquine, Angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blockers, etc.). Among these treatment options, immunosuppressants and corticosteroids are being prescribed as an initial line treatment, which is further followed by Rituxan as a last resort (Second Line) pharmacological option in the advanced stage of the disease. Detailed chapter for upcoming therapies like Obinutuzumab (Roche), Voclosporin (Aurinia Pharmaceuticals) and many others have been covered in the report.

Lupus Nephritis Market Outlook

The Lupus Nephritis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Lupus Nephritis in 7MM was found to be USD 1360 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.

Lupus Nephritis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lupus Nephritis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Lupus Nephritis Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Lupus Nephritis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Lupus Nephritis market
  • Organize sales and marketing efforts by identifying the best opportunities for Lupus Nephritis market
  • To understand the future market competition in the Lupus Nephritis market.

Table of Contents

1. Key Insights

2. Lupus Nephritis: Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of Lupus Nephritis in 2017
  • 2.2. Total Market Share (%) Distribution of Lupus Nephritis in 2028

3. Lupus Nephritis: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Causes
  • 3.3. Risk Factors
  • 3.4. Symptoms
  • 3.5. Other Clinical Manifestation
  • 3.6. Prognosis of lupus nephritis
  • 3.7. Clinical presentation of lupus nephritis
  • 3.8. Pathogenesis
  • 3.9. Classification
    • 3.9.1. LN World Health Organization 1964 Classification
    • 3.9.2. LN World Health Organization 1964 Classification
    • 3.9.3. World Health Organization (WHO) morphologic classification of lupus nephritis (modified in 1982)
    • 3.9.4. LN World Health Organization 1964 Classification
    • 3.9.5. International Society of Nephrology (ISN) and Renal Pathology Society (RPS) 2003 Classification for LN
    • 3.9.6. LN World Health Organization 1964 Classification
  • 3.10. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings

5. 7MM Total Prevalent Patient Population of LN

6. Country Wise-Epidemiology of Lupus Nephritis

  • 6.1. United States
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Prevalent Population of Lupus Nephritis
    • 6.1.3. Total Diagnosed Population of Lupus Nephritis
    • 6.1.4. Gender-Specific Prevalent Population of Lupus Nephritis
    • 6.1.5. Class- Specific cases of Lupus Nephritis
    • 6.1.6. Clinical Manifestations of Lupus Nephritis
  • 6.2. EU5 Countries
    • 6.2.1. Assumptions and Rationale
  • 6.3. Germany
    • 6.3.1. Total Prevalent Population of Lupus Nephritis
    • 6.3.2. Total Diagnosed Population of Lupus Nephritis
    • 6.3.3. Gender-Specific Prevalent Population of Lupus Nephritis
    • 6.3.4. Class- Specific cases of Lupus Nephritis
    • 6.3.5. Clinical Manifestations of Lupus Nephritis
  • 6.4. France
    • 6.4.1. Total Prevalent Population of Lupus Nephritis
    • 6.4.2. Total Diagnosed Population of Lupus Nephritis
    • 6.4.3. Gender-Specific Prevalent Population of Lupus Nephritis
    • 6.4.4. Class- Specific cases of Lupus Nephritis
    • 6.4.5. Clinical Manifestations of Lupus Nephritis
  • 6.5. Italy
    • 6.5.1. Total Prevalent Population of Lupus Nephritis
    • 6.5.2. Total Diagnosed Population of Lupus Nephritis
    • 6.5.3. Gender-Specific Prevalent Population of Lupus Nephritis
    • 6.5.4. Class- Specific cases of Lupus Nephritis
    • 6.5.5. Clinical Manifestations of Lupus Nephritis
  • 6.6. United Kingdom
    • 6.6.1. Total Prevalent Population of Lupus Nephritis
    • 6.6.2. Total Diagnosed Population of Lupus Nephritis
    • 6.6.3. Gender-Specific Prevalent Population of Lupus Nephritis
    • 6.6.4. Class- Specific cases of Lupus Nephritis
    • 6.6.5. Clinical Manifestations of Lupus Nephritis
  • 6.7. Spain
    • 6.7.1. Total Prevalent Population of Lupus Nephrites
    • 6.7.2. Total Diagnosed Population of Lupus Nephritis
    • 6.7.3. Gender-Specific Prevalent Population of Lupus Nephritis
    • 6.7.4. Class- Specific cases of Lupus Nephritis
    • 6.7.5. Clinical Manifestations of Lupus Nephritis
  • 6.8. Japan
    • 6.8.1. Assumptions and Rationale
    • 6.8.2. Total Prevalent Population of Lupus Nephrites
    • 6.8.3. Total Diagnosed Population of Lupus Nephritis
    • 6.8.4. Gender-Specific Prevalent Population of Lupus Nephritis
    • 6.8.5. Class- Specific cases of Lupus Nephritis
    • 6.8.6. Clinical Manifestations of Lupus Nephritis

7. Treatment

  • 7.1. Treatment Goals
  • 7.2. Medications
  • 7.3. General Treatment
  • 7.4. Treatment Guidelines
    • 7.4.1. American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis
    • 7.4.2. EULAR Guidelines for the treatment of Lupus Nephritis
    • 7.4.3. KDIGO Guidelines For the treatment of Lupus Nephritis

8. Unmet Needs

9. Marketed Therapies

  • 9.1. Prograf: Astellas Pharma
    • 9.1.1. Drug Description
    • 9.1.2. Regulatory Milestones
    • 9.1.3. Other Development Activities
    • 9.1.4. Safety and Efficacy
    • 9.1.5. Product Profile

10. Key Cross Competitors

11. Emerging Therapies

  • 11.1. Obinutuzumab: Roche
    • 11.1.1. Product Description
    • 11.1.2. Other development Activities
    • 11.1.3. Clinical Development
    • 11.1.4. Safety and Efficacy
    • 11.1.5. Product Profile
  • 11.2. Belimumab: GlaxoSmithKline
    • 11.2.1. Product Description
    • 11.2.2. Other Development Activities
    • 11.2.3. Clinical Development
    • 11.2.4. Safety and Efficacy
    • 11.2.5. Product Profile
  • 11.3. Voclosporin: Aurinia Pharmaceuticals
    • 11.3.1. Product Description
    • 11.3.2. Other Development Activities
    • 11.3.3. Clinical Development
    • 11.3.4. Safety and Efficacy
    • 11.3.5. Product Profile
  • 11.4. Anifrolumab: AstraZeneca
    • 11.4.1. Product Description
    • 11.4.2. Product Development Activities
    • 11.4.3. Clinical Development
    • 11.4.4. Product Profile

12. Other Promising Candidates

  • 12.1. BI 655064: Boehringer Ingelheim
    • 12.1.1. Product Description
    • 12.1.2. Clinical Development
    • 12.1.3. Safety and Efficacy
    • 12.1.4. Product Profile
  • 12.2. Iscalimab: Novartis
    • 12.2.1. Product Description
    • 12.2.2. Product Development Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Product Profile

13. Lupus Nephritis: 7 Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Size of Lupus Nephritis in 7MM
  • 13.3. Market Size of Lupus Nephritis by Therapies in First Line Patients in 7MM
  • 13.4. Market Size of Lupus Nephritis by Therapies in Second Line Patients in 7MM

14. United States Market Outlook

  • 14.1. United States Market Size
    • 14.1.1. Total Market size of LN
    • 14.1.2. Market Size of Lupus Nephritis by Therapies in First Line Patients in the US
    • 14.1.3. Market Size of Lupus Nephritis by Therapies of Second Line Patients in The US

15. EU-5 Countries: Market Outlook

  • 15.1. Germany
    • 15.1.1. Total Market size of LN
    • 15.1.2. Market Size of LN by Therapies in First Line Patients in Germany
    • 15.1.3. Market Size of LN by Therapies of Second Line Patients in Germany
  • 15.2. France
    • 15.2.1. Total Market size of LN
    • 15.2.2. Market Size of LN by Therapies in First Line Patients in France
    • 15.2.3. Market Size of LN by Therapies of Second Line Patients in France
  • 15.3. Italy
    • 15.3.1. Total Market size of LN
    • 15.3.2. Market Size of LN by Therapies in First Line Patients in Italy
    • 15.3.3. Market Size of LN by Therapies of Second Line Patients in Italy
  • 15.4. United Kingdom
    • 15.4.1. Total Market size of LN
    • 15.4.2. Market Size of LN by Therapies in First Line Patients in the UK
    • 15.4.3. Market Size of LN by Therapies of Second Line Patients in the UK
  • 15.5. Spain
    • 15.5.1. Total Market size of LN
    • 15.5.2. Market Size of LN by Therapies in First Line Patients in Spain
    • 15.5.3. Market Size of LN by Therapies of Second Line Patients in Spain

16. Japan: Market Outlook

  • 16.1. Japan Market Size
  • 16.2. Total Market size of LN
  • 16.3. Market Size of LN by Therapies in First Line Patients in Japan
  • 16.4. Market Size of LN by Therapies of Second Line Patients in Japan

17. Market Drivers

18. Market Barriers

19. Appendix

  • 19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Back to Top